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Abstract
Emerging data indicate that progesterone has multiple non-reproductive functions in the central
nervous system to regulate cognition, mood, inflammation, mitochondrial function, neurogenesis
and regeneration, myelination and recovery from traumatic brain injury. Progesterone-regulated
neural responses are mediated by an array of progesterone receptors (PR) that include the classic
nuclear PRA and PRB receptors and splice variants of each, the seven transmembrane domain
7TMPRβ and the membrane-associated 25-Dx PR (PGRMC1). These PRs induce classic regulation
of gene expression while also transducing signaling cascades that originate at the cell membrane and
ultimately activate transcription factors. Remarkably, PRs are broadly expressed throughout the brain
and can be detected in every neural cell type. The distribution of PRs beyond hypothalamic borders,
suggests a much broader role of progesterone in regulating neural function. Despite the large body
of evidence regarding progesterone regulation of reproductive behaviors and estrogen-inducible
responses as well as effects of progesterone metabolite neurosteroids, much remains to be discovered
regarding the functional outcomes resulting from activation of the complex array of PRs in brain by
gonadally and / or glial derived progesterone. Moreover, the impact of clinically used progestogens
and developing selective PR modulators for targeted outcomes in brain is a critical avenue of
investigation as the non-reproductive functions of PRs have far-reaching implications for hormone
therapy to maintain neurological health and function throughout menopausal aging.
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1. Introduction
It has become increasingly evident that the functions of gonadal steroid hormones, such as
progesterone (P4), extend well beyond reproduction. Multiple regions within the central
nervous system (CNS) beyond the hypothalamus are targeted by P4, including the hippocampus
and cortex. In recent years, both of these extrahypothalamic sites have garnered increasing
interest from endocrinologists based on accumulating evidence that P4 has potent and direct
neuroprotective and neuroregenerative effects in these brain regions while also regulating
estrogen action [1;2;3;4;5;6;7;8;9;10;11;12;13;14;15;16;17;18;19]. The non-reproductive
neural effects of P4 have substantial clinical significance, as progestogens are administered in
conjunction with estrogens in hormone therapy to counter the proliferative effect of estrogen
on the uterine epithelium. Estrogen, 17β-estradiol (E2), acts in concert with progesterone to
regulate multiple non-reproductive brain functions, such as cognition and neuroprotection
[10;20;21;22;23;24;25;26;27;28;29]. Perhaps the best-known neural effect of estrogen is its
ability to protect neurons against a wide variety of insults including glutamate excitotoxicity,
amyloid beta (Aβ), and oxidative stress [10;11;20;21;22;23;24;26;27;28;30;31;32;33;34;35].
On the other hand, the neuroprotective role of P4 [20;21;22;23;24;26;27;36;37;38;39] is just
emerging. From a reproductive gonadal hormone perspective, progesterone always acts in
concert with E2. However, this is not the case for glial derived progesterone [16;40] or for
current and future therapeutic uses of progesterone [16;40;41;42]. Here, we discuss the non-
reproductive neural functions of P4 as well as the possible mechanisms by which P4 achieves
these effects, including ‘classical’ progesterone receptor-mediated pathways and alternate
‘non-genomic’ mechanisms.
2. Progesterone Receptors from Membrane to Nucleus
The classical nuclear progesterone receptor (cPR) was first characterized in the 1970s and since
this time, has been localized to many regions of the CNS, including the hippocampus, cortex,
hypothalamus, and cerebellum [43;44;45;46;47;48;49;50;51;52]. Like most steroids, P4 exerts
its effects by binding and activating specific cellular receptors. According to the common
theory of steroid action, P4 effects are mediated by binding to its cognate receptors (PR),
classically defined as ligand-activated transcription factors. In the absence of hormone, PRs
are complexed with several chaperone molecules, including heat shock protein (Hsp) 90,
hsp70, hsp40. The interaction of PRs with the chaperones is a prerequisite for hormone binding
[53;54]. The chaperones also serve to link the PR with protein trafficking systems. Upon P4
binding, PR undergoes conformational changes, dissociates from the chaperone proteins,
dimerizes, and directly interacts with specific response elements (PREs) in the promoters of
target genes [55;56;57;58]. When bound to PREs, PRs interact with components of the basal
transcription machinery by binding to steroid receptor co-activators. These co-activators bind
to PR via a conserved LXXLL amphipathic helix or nuclear-receptor box motifs, which make
initial contacts with several helices in the AF-2 (activation function) region of the PR ligand-
binding domain [59;60]. Classical PREs are not required for P4-induced gene upregulation, as
P4 has been shown to increase expression of genes lacking these elements [61;62;63]. These
non-classical responses may occur through alternative genomic mechanisms, such as PR
tethering to the SP1 transcription factor [63] or non-genomic mechanisms, such as activation
of second messenger signaling cascades [10;11;64].
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3. Progesterone Receptors in the Brain: The Case for Multiple Isoforms
Two major isoforms of cPR are known to exist, the full-length B isoform (PRB) and the N-
terminal-truncated A isoform (PRA) [65]. Both isoforms are encoded by a single gene (with 8
exons), with translation being initiated from separate start codons (Fig. 1). Like other steroid
nuclear receptors, cPR is composed of a variable N-terminal region (encoded by exon 1), a
conserved DNA-binding domain (encoded by exons 2 and 3), a variable hinge region (encoded
by part of exon 4), and a conserved ligand-binding domain (encoded by exons 4 – 8). The N-
terminal 164-amino acids of PRB, known as B-upstream segment or BUS (absent in PRA),
constitute an additional activation function (AF-3), which is made up of two LXXLL motifs
and a conserved tryptophan residue. Although the role of cPRs in reproductive function has
been extensively studied, the receptors that mediate the neuroprotective and neurotrophic
effects of P4 have yet to be identified.
Splice variants other than the classical PRA and PRB variants have been identified [66;67].
These include variants with insertions of ‘intronic’ exons and exon-skipped variants (Fig. 2).
The intronic exons T [67] and S can be inserted between exons 3 and 4, while exons i45a and
i45b can be inserted between exons 4 and 5 (Fig. 2A). Exon-skipped variants include PR-c,
PR-s, and PR-t. These variants are generated through omission of exon 1 (PR-c) or exons 1 –
3 (PR-s and PR-t). Both PR-s and PR-t also retain 5′ untranslated exons (Fig. 2B). Other exon-
skipped mRNA variants include del 2, del 4, del 6, del 5+6, del 4+6, del 4+5+6, del 3+4, and
del 3+4+5+6. Interestingly, some of these variants have a defective DNA-binding domain and
also lack the nuclear localization signal (NLS). PR splice variants lacking NLS, which would
be expected to result in cytoplasmic localization, and contain the intact proline rich (PXXP)
domain, would be expected to displace the intramolecular occupation of SH3 in Src, enabling
them to activate Src and mitogen-activated protein kinases (MAPK) in the cytosol. PRs lacking
a functional DNA-binding domain and a NLS could serve as a membrane-associated PR.
Although cPR is expressed in the hippocampus and frontal cortex [43;44;45;46;47], P4 effects
have been reported in the CNS of PR knockout mice, indicating that receptors other than cPR
may mediate P4 signaling in the brain [68]. A novel P4-binding protein that is distinct from the
cPR has been identified as a membrane protein, known as 7TMPR for its seven transmembrane
domains [69;70], has characteristics of a G protein-coupled receptor. When bound to progestin,
this receptor blocks the activity of adenylyl cyclase, the enzyme that catalyzes production of
the intracellular second-messenger cAMP [70]. Three isoforms of 7TMPR have been
identified– 7TMPRα, β, and γ. The open reading frames (ORFs) of 7TMPRα from human, pig,
and mouse are 1038 – 1053 nucleotides in length and encode peptides 346 – 350 amino acids
in length. These peptides are similar in size to 7TMPR of spotted seatrout (352 amino acids)
and zebrafish (354 amino acids). The ORFs of 7TMPRβ from mammals, zebrafish, and
Xenopus laevis are 1064/1065 nucleotides in length and encode 352–354-amino acid peptides.
The 7TMPRγ are slightly shorter, at approximately 330 amino acids.
An additional putative membrane-bound PR has been cloned in multiple different species. The
initial isolation and cloning of this protein from pig and rat revealed the presence of a single
transmembrane domain. Humans contain two orthologous genes, hpr6.6 (chromosome X, 195
amino acids) and Dg6 (chromosome 4, 223 amino acids). The rat homologue is a 25 kDa, 223-
amino acid protein (25-Dx) possessing a hydrophobic domain of 14 residues and a proline-rich
domain in the N-terminal region. Independent isolation of rat adrenocortical innerzone-specific
antigen (IZAg) by affinity chromatography revealed this protein to be identical to 25-Dx.
Overexpression of 25-Dx in CHO cells has been shown to increase P4 binding to the
microsomal fraction [71]. This 25-Dx-enriched microsomal fraction has moderate affinity for
testosterone and weak affinity for corticosterone and cortisol. In contrast, it does not bind to
either estradiol (E2) or aldosterone. In human sperm, blockade of 25-Dx with a specific
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antibody inhibits P4-induced increases in intracellular Ca2+, providing further support that this
protein serves as a membrane PR [71].
4. Localization of Progesterone Receptors in the Brain
Progesterone receptors are broadly expressed throughout the brain, with no apparent restriction
to specific cell types. Nevertheless, PR expression may vary depending on the brain region,
cell type, or hormonal status (Fig. 3). Both of the classical PR isoforms (PRA and PRB) are
expressed in the hippocampus and frontal cortex of the rat (Fig. 3). PR immunoreactivity is
especially high within the bed nucleus of the stria terminalis (BST), in particular the medial
division of the medial nucleus of the BST (the principal nucleus of the BST). Immunoreactivity
is lower in the intermediate and lateral divisions of the medial nucleus of the BST. In the
centromedial amygdala, PR expression is prominent in the posterodorsal part of the medial
amygdaloid nucleus, but lower in surrounding areas. No sex differences have been observed
in PR expression in the BST and centromedial amygdala [72]. In the brainstem, PR
immunoreactivity is present in the norepinephrine neurons of the nucleus tractus solitarius, the
region from which projections to the hypothalamic supraoptic nuclei arise. Guerra-Araiza et
al. have used quantitative RT-PCR analysis to characterize sex differences in the regulation of
PR isoform expression by sex steroid hormones in the rat cerebellum [44]. PR isoform
expression in female rats was not altered by estrogen or P4, while PRA was selectively induced
by estrogens in the male cerebellum. Similarly, in the rat hippocampus and olfactory bulb,
E2 induces PRA isoform expression, whereas P4 does not affect the expression of any PR
isoforms [43;44]. In rodents, PR is present in the ventromedial hypothalamus [73]. Auger et
al. have reported PR-immunoreactive cells within the preoptic area, the ventromedial and
dorsomedial nucleus of the hypothalamus, and the arcuate nucleus of the female rat [72].
Dot blot analysis of 7TMPR expression in human tissue has shown that the α form (from a
testicular library) is mainly localized to reproductive tissues such as the placenta, testis, and
ovary. In contrast, the γ form (from a colon library) is present in the kidney, fetal kidney, colon,
a lung carcinoma, and HeLa 53 cells [70]. The β form (from a brain library) is exclusively
localized to neural tissues [70]. These include the cerebral cortex, cerebellum, caudate nucleus,
thalamus, pituitary gland, and spinal cord, as shown by dot blot hybridization or tissue array
with Northern hybridization.
5. Mechanisms of Progesterone Action
Progesterone produces multiple effects in the brain through three principle mechanisms:
regulation of gene expression, modulation of neurotransmitter systems, and activation of
signaling cascades. Classification of the determinant pathways and identification of the specific
receptors mediating activation of each of these pathways would be expected to uncover new
targets and enable development of improved therapeutic strategies. The effects of P4 are
historically thought to be mediated by PRA or PRB-induced gene transcription [55;65;74].
Available evidence suggests that PRA and PRB shuttle between the nucleus and the cytoplasm,
with ligand binding inducing interactions between the receptor and nuclear co-activators [55;
74]. PRA and PRB differentially regulate gene transcription, increasing the complexity of this
regulatory system [75;76]. For example, PRA is a less potent transactivator than PRB. Also,
PRA exerts transrepressional activity on PR-B in a promoter- and cell type-dependent manner
[75;76]. The P4-inducible genetic network is further refined by the expression of PR splice
variants with variable ligand affinities and transactivational activities [77].
The effects of P4 may be attributed to mechanisms apart from the ‘classical’ gene transcription
mediated by PRA and PRB. Recently, P4 binding sites have been detected at the surface of
hypothalamic and spinal neurons [68;78]. These binding sites, identified as 25-Dx (also known
as PGRMC1), mediate the antiapoptotic actions of P4 in granulose and luteal cells [79;80]. In
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the ovary, 25-Dx complexes with the plasminogen activator inhibitor RNA-binding protein 1
(25-Dx/SERBP1) to activate cGMP-dependent protein kinase [81]. P4 signaling may also be
mediated by several putative Src homology domains present in 25-Dx [82]. However, the P4-
activated signaling pathways that are mediated by 25-Dx have yet to be determined in neurons.
Like 25-Dx, the seven transmembrane putative progesterone receptor 7TMPR may regulate
P4 signaling. The 7TMPR has been shown to activate a pertussis toxin-sensitive inhibitory G
protein, resulting in activation of the MAPK pathway through inhibition of cAMP production
[83;84].
Progestereone and its 5alpha-reduced derivatives dihydroprogesterone (DHP) and
tetrahydroprogesterone (THP or allopregnanolone), can promote Schwann cell proliferation
and activation of the myelinating program of these cells [85]. Melcangi and colleagues
demonstrated that P4 and its derivatives increased expression of the transcription factors
Sox-10 and Krox-20, both of which play a key role in Schwann cell physiology and in their
myelinating program. Western blot analyses indicated that Krox-20 was increased after 3 h of
treatment with P4, dihydroprogesterone, or tetrahydroprogesterone, whereas P4 or
dihydroprogesterone stimulated expression of Sox-10 after 6 h of exposure. Analysis of rat and
human promoters for these two transcription factors indicated that putative P4-response
elements are present in the Krox-20 gene but not in Sox-10. These findings suggest that P4 and
its neuroactive derivatives could coordinate the Schwann cell-myelinating program utilizing
different intracellular pathways [85].
Although mPR binds P4 with high selectivity and affinity, it does not bind many of the synthetic
progestins including norethisterone, norgestrel, promesgestrone, and demegestone [83]. This
differential binding may underlie the distinct differences in neuroprotection and MAPK
activation elicited by P4 and synthetic progestins [10;11]. However, the neuronal expression
of mPR has not yet been determined. The various progestin-activated signaling pathways can
be combined synergistically or antagonistically in an intriguing number of ways to regulate
development, survival, and electrical activity in the CNS. Each step of this signaling network
can be influenced in a cell type- or brain region-specific manner through alterations in receptor
expression or ligand structure, opening up a wide array of therapeutic possibilities.
The MAPKs modulate cellular differentiation, proliferation, survival, and death. Activation of
the MAPK, extracellular signal regulated kinase (ERK), is required for E2-induced
neuroprotection (Figure 4) [33]. We and others have demonstrated that both E2 and P4 activate
the ERK signaling pathway [10;11;28;33]. However, nuclear activation of ERK is not induced
by medroxyprogesterone acetate (MPA), a progestin that lacks neuroprotective effects [11].
Phosphorylation of the MAPK substrate, cAMP response element binding protein (CREB), is
associated with increased resistance to ischemic injury [86;87], and CREB is activated in
response to ovarian hormones [88;89;90;91;92;93]. CREB, in turn, can upregulate bcl-2
expression [87;91]. Accordingly, E2 and P4 upregulate bcl-2 in hippocampal neurons [10]. In
contrast to P4, MPA does not activate CREB, nor does it increase Bcl-2 expression [10]. On
the contrary, MPA blocked E2-induced CREB activation and Bcl-2 upregulation in primary
hippocampal neurons.
Estrogen and P4 simultaneously activate the MAPK/ERK pathway as well as an alternate pro-
survival pathway, the Akt pathway [28]. Activation of Akt by E2 and P4 in cortical slice cultures
is associated with increase neuronal survival [28]. However, use of mixed cell types in these
slice cultures precludes differentiation between direct and indirect effects of the steroids on
neural cells. In primary hippocampal neuron cultures, E2 and P4 directly activate Akt in
neurons. Western blot analysis of whole-cell lysates revealed that E2 (10 ng/mL) and P4 (10
ng/mL), either alone or in combination, significantly increased Akt phosphorylation within 20
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min of treatment. Treatment of primary hippocampal neurons with MPA did not alter Akt
phosphorylation, but blocked E2-induced Akt phosphorylation.
More recently, it has been recognized that these steroids also regulate metabolic functions
sustaining the energetic demands of this neuronal activation [94;95;96;97;98;99;100;101].
Recent findings from Nilsen and colleagues indicate that P4 significantly increased
mitochondrial respiration 24 hrs following a single in vivo exposure at a magnitude comparable
to E2 [7]. Consistent with an increase in oxidative respiration, P4 and E2 significantly increased
COXIV enzyme activity and expression of COXIV mRNA. Both P4 and E2 reduced free radical
leak indicating greater efficiency of electron transport, which was evidence in a reduced
generation of free radicals, P4 and E2 induced a significant reduction in mitochondrial lipid
peroxidation. The reduction in lipid peroxidation suggests the activation of mechanisms
beyond solely mitochondrial efficiency. P4 induced a significant increase in MnSOD
expression as did E2 and E2/P4. In contrast, the expression of peroxiredoxin V was only
increased by E2 but not in the P4-and P4 blocked the E2 induction of peroxiredoxin V. These
results indicate that both P4 and E2 can promote dismutation of the superoxide anion O2•- by
increasing MnSOD to form H2O2 whereas only E2 induces peroxiredoxin V that promotes
clearance of H2O2 and prevention of oxidative damage. Further, P4 and E2 directly regulate
mitochondrial function and are not due to an increase in the number of mitochondria as neither
P4 nor E2 nor their combination induced evidence for mitochondrial biogenesis. While P4 was
as efficacious as E2, the combination of P4 and E2 led to reduced efficacy. On all outcome
measures, the combination of P4 and E2 resulted in a substantial decrement in response
magnitude.
6. Neuroprotective actions of progesterone and progestin in the CNS
P4 has established neuroprotective actions that likely involve several different mechanisms.
Anxiolytic effects are one way by which P4 can reduce neural injury. Diverse stimuli including
kainate [102], pilocarpine [103], and pentylenetetrazole [104] elicit stereotypic seizure
behaviors and within several hours to a few days, significant neuronal loss in select brain
regions such as the hippocampus. In these paradigms, P4 treatment attenuates not only seizure
behaviors [105, Rhodes, 2004 #2538; 106], but also neuronal injury [107]. The primary
mechanism of neuroprotection in these models appears to involve the P4 metabolite,
allopregnanolone (APα, also known as 5α-pregnan-3a-ol-20-one and 3a,5a-
tetrahydroprogesterone). P4 is metabolized to APα following the sequential action of 5α-
reductase and 3α-hydroxysteroid dehydrogenase. APα acts as potent modulator of gamma-
aminobutyric acid subtype A (GABAA) receptors, increasing chloride conductance evoked by
GABA [1;108]. This serves to decrease excitatory signaling and thus, antagonize seizure
activity. Support for an APα-mediated mechanism of P4 neuroprotection is provided by the
finding that i) APα is as effective as P4 in seizure paradigms [107;109;110;111;112;113] and
ii) molecular [114;115] or pharmacological [109;113;116;117] inhibition of P4 metabolism to
APα blocks the protective actions of P4. Interestingly, APα has also been implicated in the
neuroprotective effects of P4 following oxygen-glucose deprivation of rat Purkinje cells
[118] and traumatic injury [23;119;120;121].
P4 likely triggers multiple neuroprotective mechanisms. For example, in neuronal cultures,
P4 activates MAPK/ERK [10;11;28] and Akt [28] signaling pathways, both of which are
associated with neuroprotection [28;33;122]. Recent evidence suggests that, in spinal cord
injury models, P4 neuroprotection is associated with upregulation of brain-derived
neurotrophic factor (BDNF) [98;99;100] increased levels and activity of choline
acetyltransferase [100], and a reduction in mitochondrial dysfunction [101]. In cerebral
ischemia models, the protective effects of P4 are attributed, in part, to suppression of
inflammatory responses and nitric oxide synthase-2 expression [123]. In addition to its direct
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effects on neurons, P4 may exert indirect neuroprotective effects by acting on non-neuronal
target cell populations. For example, P4 reduces blood brain barrier leakage [14], decreases
glial activation [124], and increases myelination [125;126].
P4 and E2 are known to modulate the activity of one another, sometimes antagonistically. Thus,
it is of interest to determine the effect of P4 and progestogens on the neuroprotective effects
of E2. The antagonistic relationship between P4 and E2 is illustrated by the finding that P4 can
block E2-induced increases in spine density in the hippocampus [18;127]. P4 can also attenuate
E2-induced upregulation of BDNF, neurotrophin 3, and nerve growth factor in the entorhinal
cortex, but not in hippocampus, of female rats [128]. P4 reverses estrogen-induced
enhancement of spatial memory in ovariectomized female rodents (Bimonte-Nelson et al.,
2006). Recent results from our group demonstrate that both P4 and MPA block the
neuroprotective effect of E2 in the hippocampus following kainate lesion in young female
rodents [129] and reproductively senescent female rodents (Carroll and Pike, unpublished
observations). P4 treatment decreases the estrogen receptor hybridization signal in monkey
brain [130], indicating that P4 may limit E2 signaling. However, in both a systemic kainate
lesion model [131] and an ischemic stroke model [132], acute P4 treatment was not
neuroprotective and did not significantly affect E2 neuroprotection.
The neuroprotective action of P4 in traumatic brain injury has been extensively studied by
Stein and colleagues. Results of their extensive body of work indicate that a single injection
of P4 attenuated cerebral edema when administered during the first 24 h after traumatic brain
injury (TBI) in rats whereas 5 days of P4 injection resulted in improved spatial learning
performance and reduced sensory neglect [133]. In subsequent analyses, Grossman et al.,
[124] found that P4 reduced edema levels, as in previous studies, while increasing the
accumulation of activated microglia in traumatic brain injured rat brain [6]. However, a parallel
analysis indicated that P4 and allopregnanolone reduced both IL-1beta and TNF-alpha 3 h post-
traumatic brain injury, when the expression of these cytokines peaked in the untreated animals
[6]. Progesterone-induced reduction in inflammatory cytokines was also observed in a medial
frontal cortex model of traumatic brain injury [12]. Progesterone inhibited the injury-induced
rise in complement factor C3, GFAP, and nuclear factor kappa beta (NFkappaB) [12]. The
paradox of the dual effect of P4 to induce accumulation of activated microglia and reduce
inflammatory immune cytokines remains unresolved.
The contributions of gender and gonadal hormones in the cascade of events following brain
injury were investigated and revealed that normally cycling females exhibited significantly
less edema than males following traumatic brain injury and that pseudopregnant females were
virtually spared from post-injury edema. Subsequent studies of ovariectomized females, with
or without hormone treatment, indicated that the reduction of cerebral edema was associated
primarily with the presence of circulating progesterone [134]. The Stein group then went onto
to determine whether P4 metabolite neurosteroids mediated the neuroprotection of exogenous
or endogenous P4. One day after traumatic brain injury, both P4-treated (16 mg/kg) and
allopregnanolone (8 or 16 mg/kg)-treated rats showed less caspase-3 activity, and rats treated
with allopregnanolone (16 mg/kg) showed less DNA fragmentation in the lesion area,
indicating reduced apoptosis. Nineteen days after the injury, rats treated with P4 or
allopregnanolone (8 or 16 mg/kg) showed no difference in necrotic cavity size but had less cell
loss in the medio-dorsal nucleus of the thalamus and less learning and memory impairments
compared with the injured vehicle-treated rats. The results from their analyses indicated that
P4 and allopregnanolone had similar neuroprotective efficacy after traumatic brain injury, but
that allopregnanolone appeared to be more potent than P4 in promoting CNS repair [120]. A
follow-up study compared the effects of P4 and its metabolite, allopregnanolone, on the early
injury cascade (apoptosis) and long-term functional deficits after traumatic brain injury
[119]. Progesterone (16 mg/kg) or allopregnanolone (4, 8, or 16 mg/kg) were injected at 1 h,
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6 h, and then for 5 consecutive days after bilateral contusions of the frontal cortex in adult male
rats. Within one day after injury, P4 and allopregnanolone reduced expression of pro-apoptotic
proteins caspase-3 and Bax, and apoptotic DNA fragmentation. Progesterone and
allopregnanolone also reduced the size of glial fibrillary acid protein (GFAP)-positive
astrocytes at the lesion site 24 h after injury. At 19 days post-injury, rats given P4 or
allopregnanolone (8 mg/kg) showed improved performance in a spatial learning task compared
to injured rats given only the vehicle [119].
The extensive body of basic science in vivo evidence indicating that P4 was highly efficacious
in reducing or preventing the neurological consequences of traumatic brain injury [42], led
Stein and colleagues to conduct a clinical trial of P4 in human victims of moderate to severe
coma associated traumatic brain injury [19]. In a phase II, randomized, double-blind, placebo-
controlled trial conducted at an urban Level I trauma center with 100 adult trauma patients who
arrived within 11 hours of injury with a postresuscitation Glasgow Coma Scale score of 4 to
12 (scores associated with moderate to severe degrees of coma) were enrolled with proxy
consent. Neurologic outcome was assessed 30 days postinjury. Seventy-seven patients received
progesterone; 23 received placebo. No serious adverse events were attributed to progesterone.
Adverse and serious adverse event rates were similar in both groups, except that patients
randomized to P4 had a lower 30-day mortality rate than controls. Thirty days postinjury, the
majority of severe traumatic brain injury survivors in both groups had relatively poor Glasgow
Outcome Scale-Extended and Disability Rating Scale scores. Moderate traumatic brain injury
survivors who received P4 were more likely to have a moderate to good outcome than those
randomized to placebo. The authors concluded that results of this small study, P4 caused no
discernible harm and showed potential benefit [19].
7. Progesterone regulation of memory and neuronal excitability
After more than three decades of research, it is now well established that the ovarian hormone,
E2, exerts a wide variety of effects on neural structures and function, particularly within the
hippocampus [135;136;137]. Electrophysiological studies have shown that E2 enhances
hippocampal CA1 synaptic transmission and plasticity by increasing NMDA and AMPA
receptor activity, which results in neuronal excitation [138;139;140;141]. While the above
studies have focused exclusively on the effect of E2 on brain structure and function, more recent
studies have investigated the effect of P4 and its neuroactive metabolites APα and pregnanolone
(PREG) on cognitive function and neural excitability.
Long-term potentiation (LTP) is considered to be the best cellular model of memory trace
formation in the brain, at least for certain forms of memory in the hippocampus and neocortex
[142;143;144]. The phenomenon opposite to LTP is long-term depression (LTD), which was
first demonstrated in cerebellar cortex by Ito in 1982 [145]. LTD has also been demonstrated
in the hippocampus and neocortex and like LTP, is considered a mechanism for memory storage
[146;147]. Although the molecular mechanisms underlying LTP (and LTD) have been
extensively investigated, there is a relative paucity of studies demonstrating the critical role of
LTP in behavioral learning and memory [148]. Nonetheless, LTP (and LTD) are the best current
models of synaptic plasticity, which may underlie memory storage [149]. In the CA1, the most
widely studied form of LTP involves glutamate activation of NMDA receptors, which
augments AMPA receptor function for the expression and maintenance of LTP. However, this
is not the sole form of LTP in the CA1, as Teyler and associates have demonstrated a form of
tetanus-induced LTP in the CA1 that is independent of NMDA receptors and involves voltage-
dependent calcium channels [150].
Few studies have examined the acute effects of P4 on synaptic transmission and plasticity, with
the results of these studies being mostly contradictory. P4 (10 μM) reportedly has no effect on
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LTP (CA1 slices from 4 week-old rats), but no non-drug control was used in this study [151].
In another study, P4 (8 – 10 M, in CA1 slices) significantly enhanced synaptic transmission,
as seen by an increased field potential and population spike amplitude; however, following a
seizure-induced tetanus, P4 decreased the field potential, the population spike responses, and
the duration of after-discharges [152]. In whole cell patch clamp of pyramidal neurons from
slices of prelimbic cortex, P4 (100 μM) had no effect on the frequency of excitatory
postsynaptic currents (EPSCs), but inhibited dopamine-induced increases in EPSCs [153].
P4 dose-response functions were not obtained in any of these studies. In primary hippocampal
neurons, P4 as well as E2 enhances glutamate-mediated increases in intracellular calcium, with
E2 having a greater effect. P4 appears to interfere with E2 enhancement of synaptic
transmission, as seen by the finding that co-treatment with P4 and E2 enhances glutamate-
mediated increases in intracellular calcium to the same degree as P4 alone [10].
Clinical investigations have been performed to understand the effect of P4 on moods associated
with premenstrual dysphoric disorder (PMDD) [154]. PMDD is defined in the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV, APA 1994) as a cluster of both negative
mood symptoms and physical symptoms that occur during the luteal phase of the menstrual
cycle (when P4 and APα levels are high) and disappear several days following the onset of
menstruation (when P4 and APα levels are low). The increase in P4 (and APα) levels that occurs
during the luteal phase of the menstrual cycle is considered to be at least partly responsible for
the negative mood changes associated with PMDD [154;155]. Although ovarian steroids are
required for onset of premenstrual symptoms, women with PMDD are thought to exhibit an
altered GABA receptor sensitivity [156]. Support for the association of P4 with negative mood
symptoms comes from the finding that postmenopausal women exhibiting intermediate APα
plasma concentrations subjectively rated themselves as having significantly more negative
mood symptoms during P4 treatment than during treatment with unopposed E2 or placebo
[157]. P4 concentrations (measured via radioimmunoassay) in the amygdala, cerebellum, and
hypothalamus are significantly higher in fertile women in the luteal phase of menstruation than
in postmenopausal controls [158]. Moreover, in fertile women, APα concentrations are highest
in substantia nigra and basal hypothalamus, suggesting that the pattern of steroid secretion
during the menstrual cycle is reflected in specific brain tissues [158].
P4 and APα are known to regulate cognitive function, particularly those functions related to
mood and/ or associated with changes in the menstrual cycle (e.g., postpartum depression,
major depression, epilepsy) [159]. The GABAergic system also participates in major
depression (for review, see [160]. The GABAA receptor mediates the majority of rapid (1 –
100 ms) synaptic inhibition in the mammalian brain, and APα and PREG exert both anxiolytic
and anesthetic effects by enhancing GABA-stimulated chloride conductance. This enhanced
conductance serves to hyperpolarize postsynaptic membranes and results in neuronal inhibition
[161;162]. Recent evidence suggests that specific neurosteroids ‘fine-tune’ neural inhibition
via the GABAergic system [163]. In another recent study, the ability of P4 to influence
cognition and memory of biologically salient stimuli was investigated in healthy young women
[164]. Here, a single dose of P4 was orally administered to women who were then asked to
memorize and recognize faces while undergoing functional magnetic resonance imaging. The
results revealed that P4 decreases recognition accuracy without affecting reaction times. P4
also decreased amygdala and fusiform gyrus activity elicited by faces during memory
encoding, supporting the conclusion that P4 alters memory function by influencing amygdala
activity [164;165].
In animals, P4 and its metabolites severely impair learning and memory performance
immediately following administration in the Morris water maze test [166;167]. Although the
mechanism underlying this impairment is unknown, a recent study demonstrated that
pretreatment of rats with APα induces a partial tolerance against the acute effects of APα in
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the Morris water maze test [168]. These authors suggest that prolonged exposure to APα in
women (e.g., pregnancy, postmenopausal hormone replacement therapy, menstrual cycle) may
alter cognitive behavior such as learning and memory, possibly through a GABAergic-
dependent mechanism.
Excitatory synapses, which can be approximated by dendritic spine density, serve as the
substrate for learning and memory. A significant amount of literature describes the effects of
estrogen and P4 on dendritic spine formation in hippocampal pyramidal neurons [169]. In rats,
ovariectomy results in a decrease (over 6 days) in the density of dendritic spines, which can
be prevented and reversed by E2 treatment [18]. Administration of P4 after estrogen treatment
initially augments the effects of E2 (and sexual behavior such as lordosis). However, 6 h later,
P4 rapidly decreases spine density to the very low levels, which are equivalent to levels seen
18 h after ovariectomization. Indeed, the number of dendritic spines in specific brain regions
fluctuates over the 4 – 5 day estrous cycle in accordance with estrogen and P4 levels [170].
The down regulation of dendritic spines by P4 is blocked by the P4 antagonist, RU-38486,
consistent with the presence of intracellular PRs in the hippocampus. Electron microscopic
studies have demonstrated the presence of non-nuclear PRs in glia and dendritic spines in the
hippocampus [135]. Also, P4 acts directly on GABAergic receptors to enhance GABA
inhibition and thus, counter the effects of E2 [127;171].
During the ovulatory cycle, extensive tissue remodeling occurs throughout the body, including
certain brain regions. Some of the most profound changes occur in uterine tissue, which
undergoes extensive angiogenesis and cell proliferation during the follicular phase. In the
absence of a blastocyst, the uterine growth phase is terminated by resorption or exfoliation of
epithelial and vascular cells. Numerous inflammatory mediators are cyclically regulated during
both the growth and exfoliative phase [172]; [173]; [174]. These cyclically-regulated genes
encode diverse proteins, many of which function in apoptosis such as Fas, caspase-3, M30
[175], complement C3 [174] [176], and secretory leukocyte proteinase inhibitor (SLPI)
[177]. Progestins regulate the expression of many of these genes. For example, progestins
antagonize estrogens in regulation of C3 [174] [176], whereas P4 acts in synergy with the
proinflammatory cytokine, IL-1, to induce expression of SLPI, an antimicrobial peptide
important in host defense [177].
In contrast to uterine remodeling during the estrous cycle, brain ‘remodeling’ is more modest
and does not involve major changes in the proportions of cell populations. In the rodent
hippocampus, certain synaptic beds implicated in declarative memory undergo striking,
transient changes during the estrous cycle. The dendritic spine density of CA1 pyramidal cells
undergoes cyclic changes, which are strongly correlated with sensitivity to NMDA receptor-
mediated synaptic responses [137]; [136]. There is also increased aggregation of MAP2 in
apical dendrites [178] as well as an increased expression of syntaxin, synaptophysin
(presynaptic), and spinophilin (postsynaptic) [179]. The increase in dendritic spines is driven
by elevations in E2 during the preovulatory follicular phase, whereas the rapid regression of
these spines after ovulation depends upon elevation of P4 from the corpus luteum [18].
Administration of the PR antagonist, RU 486, during proestrus inhibits the decrease in spine
density after proestrus [18]. Like the CA1, the hypothalamic arcuate nucleus undergoes
remodeling in response to the preovulatory luteinizing hormone surge. In this region, astrocyte
volume changes have been associated with altered GABAergic contacts on gonadotropin-
releasing hormone axons [180]; [181]. There is now a significant literature concerning the
effects of estrogen and progesterone on dendritic spine formation in hippocampal pyramidal
neurons [169]. In brief, ovariectomy (in rats) causes a decrease (over 6 days) in the density of
dendritic spines, which can be prevented and reversed by estradiol treatment [18]. Progesterone
treatment subsequent to estrogen treatment initially augments the effects of estradiol (and
sexual behavior, e.g., lordosis) and then (after 6 h) results in a rapid decrease in spine density
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to the very low values seen in ovariectomized animals by 18 h. Indeed, the number of dendritic
spines in specific brain regions fluctuates over the 4-5 day estrous cycle in accordance with
estrogen and progesterone levels [182]. The down regulation of dendritic spines by
progesterone is blocked by the progesterone antagonist, RU-38486, consistent with the
presence of intracellular progesterone receptors (PR). Electron microscopic studies also
indicated the presence of non-nuclear PRs in glia and dendritic spines in hippocampus [135].
Progesterone can also act directly on GABAergic receptors to enhance GABA inhibition, thus
countering the effects of E2 [127;171].
8. Progesterone regulation of glial cell function and response
Progesterone regulates responses in each of the major glial cell types, astrocytes, microglia,
oligodendrocytes and Schwann cells. During the estrous cycle sstrocyte size varies with CA1
astrocytes shrinking immediately before increases in spine density [183]. Astrocytes also
decrease in size in the rostral preoptic location of gonadotropin-releasing hormone cell bodies
[184]. Astrocyte size is strongly associated with the expression of glial fibrillary acidic protein
(GFAP), which varies during the estrous cycle in the dentate gyrus [185]. Progesterone, and
its neurosteroid metabolite dihydroprogesterone induced a significant elevation of GFAP
mRNA levels in type 1 astrocytes within hours of exposure with direct administration of
dihydroprogesterone inducing an increase within 2 h whereas P4 required 6 h for increased
GFAP expression. These findings suggest that the effect of P4 is likely due to metabolism to
DHP. The requirement for conversion of P4 to increase GFAP protein level was confirmed
through the addition of finasteride (a specific blocker of the 5 alpha-reductase) which
completely abolished the effect of P4[186].
In astrocytes, P4 regulates production of multiple proteins including those shown to be involved
in regulating synaptic plasticity such as ApoE which is secreted by astrocytes may be an
important player in synaptic remodeling, since this protein transports cholesterol and other
lipids to outgrowing neurites [187]. Glial apoE mRNA changes cyclically in the CA1 and
arcuate nucleus [188]; [189], supporting a role for this protein in synaptic remodeling. During
pregnancy, two-fold increases in uterine apoE levels are associated with increased import of
maternal lipids [190]. Also, estrogen-dependent sprouting of perforant path fibers to the
hippocampus is absent in apoE-knockout mice [191] [189] [192]. Complex heterotypic cellular
interactions that occur in response to ovarian steroids extend beyond astrocytic-neuronal
interactions. Although ApoE is secreted by astrocytes, astrocytic responses to estrogen require
interactions with microglia, as evidenced in monotypic astrocyte cultures which are much less
sensitive to estrogen than mixed glial cultures containing microglia [185]. Besides E2,
Premarin® also induced ApoE expression in mixed glia [193]. P4 increased ApoE secretion in
macrophages (microglia also express apoE mRNA) by acting on the C-terminal lipid-binding
domain of ApoE to block its intracellular degradation [194]. The effect of other clinical
progestins on glial apoE expression remains to be determined.
In many organ systems, estrogen actions are attenuated or antagonized by progestins. As
discussed above, E2 drives increases in CA1 spine density (growth phase), while P4 promotes
the regression of dendritic spines (during the proestrus to estrus transition). In mouse
hippocampal slice cultures, mossy fiber sprouting into the molecular layer of the dentate gyrus
is induced by deafferentation of the entorhinal cortex [192]. In this system, E2 (100 pM)
increases sprouting by 75%. This concentration of E2 also induces maximal apoE induction in
mixed glia [195]. E2-dependent sprouting can be blocked by P4 or tamoxifen [192]. P4 appears
to differ from MPA in its ability to regulate synaptic plasticity. Preliminary results from our
laboratory show that MPA, but not P4, inhibits E2-mediated sprouting. This difference is
consistent with recent findings by Nilsen and Brinton that P4, but not MPA, is neuroprotective
against excitotoxicity and stimulates nuclear activation of ERK. Further, MPA, but not P4,
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blocked the neuroprotective effects of E2 [11]. Additional studies will be necessary to evaluate
the differences and similarities of MPA and P4.
In some models, P4 has been reported to have anti-inflammatory activities. After stab wounds,
P4 decreased reactive astrocytes to a greater extent than E2, but less than pregnenolone[196;
197]. In a model of cerebral concussion, male rats given an i.p. injection of P4 of had less edema
[124] and lipid peroxidation [14] than their untreated counterparts. On the other hand, P4 had
a negligible effect on glial activation or neuronal loss in this model [124]. In accord with
findings from the cerebral concussion model, P4 inhibited the level of clinical neurogenic
edema, possibly by reducing meningeal release of substance P [198]. Of course, P4 has many
complex interactions with neurotransmitters, which may underlie this and other anti-
inflammatory effects (e.g., activation of the GABA receptor by P4 and other C21 steroids
[199].
Progesterone regulation of myelination is now well documented and is a compelling example
of the profound direct effects of P4. The sciatic nerve, and Schwann cells in particular, are
capable of synthesizing P4 and possess the enzymes necessary to convert P4 to the 5alpha-
reduced and the 3alpha-5alpha-reduced derivatives of P4: dihydroprogesterone and
tetrahydroprogesterone [200]. Progesterone receptor has been detected in both sciatic nerve
and in Schwann cell cultures. P4 and its metabolite neurosteroids regulate expression of two
major proteins of the peripheral nervous system (PNS): the glycoprotein Po (Po) and peripheral
myelin protein 22 (PMP22). Melcangi and colleagues have shown that: (a)
dihydroprogesterone enhanced the low mRNA levels of Po in the sciatic nerve of aged male
rats; (b) P4 and its derivatives stimulates the gene expression of Po in the sciatic nerve of adult
rats and in Schwann cell cultures; (c) tetrahydroprogesterone increased PMP22 gene expression
in the sciatic nerve of adult rats and in Schwann cell cultures. They further demonstrated that
P4 and its derivatives control Po gene expression via the PR, while tetrahydroprogesterone
modulated expression of PMP22 through the GABAA receptor[200]. Melcangi and coworkers
went on to demonstrate that P4 and its derivatives regulate other myelin proteins [i.e., myelin-
associated glycoprotein (MAG) and myelin and lymphocyte protein (MAL)] in sex-specific
cultures of rat Schwann cells [9]. Progesterone or dihydroprogesterone induced a stimulatory
effect on P0 mRNA levels in male but not in female Schwann cells. In contrast, treatment with
tetrahydroprogesterone increased gene expression of P0 in female derived Schwann cells. A
similar sex-difference was also evident for other myelin proteins. PMP22 expression was
increased by P4 in male derived Schwann cell cultures, whereas tetrahydroprogesterone
induced an increase of mRNA levels in female derived cells. Moreover, MAG was stimulated
by tetrahydroprogesterone treatment in male cultures only, whereas MAL expression was
unaffected by neuroactive steroid treatment in both male and female cultures. Collectively
these findings indicate that P4 and its metabolite neuroactive steroids on regulate myelin protein
expression in a sexually dimorphic manner. This finding might represent an important
background for sex-specific therapies of acquired and inherited peripheral neuropathies [9;
200]. Melcangi and colleagues pursued the relevance of these findings for age-associated
myelin loss and morphological alterations of myelinated fibers in the sciatic nerve of 22-24-
month-old male rats. The sciatic nerves of untreated old male rats, showed a general
disorganization and a significant reduction in the density of myelinated fibers, compared to
nerves from 3-month-old male rats. The effect of aging was particularly evident in myelinated
fibers of small caliber (<5 micron in diameter). In addition, the sciatic nerves of old rats showed
a significant increase in the number of fibers with myelin infoldings in the axoplasm and in
the number of fibers with irregular shapes. Treatments of old rats with P, DHP and THP resulted
in a significant increase in the number of myelinated fibers of small caliber, a significant
reduction in the frequency of myelin abnormalities and a significant increase in the g ratio of
small myelinated fibers. Furthermore, P4 significantly reduced the frequency of myelinated
fibers with irregular shapes. Results of these in vivo animal studies indicate that in the aged
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male rat P4 and its neuroactive metabolites reduced aging-associated morphological
abnormalities of myelin and aging-associated myelin fiber loss in the sciatic nerve[125].
In the central nervous system P4 and its neurosteroid metabolites were found to promote glial
functions, such as the synthesis of myelin proteins. In glial cell cultures prepared from neonatal
rat brain, P4 increased the number of oligodendrocytes expressing myelin basic protein and
the 2′,3′-cyclic nucleotide-3′-phosphodiesterase (CNPase), the third most abundant myelin
protein in the CNS [40]. The role of P4 in myelination is extensively covered in several excellent
reviews by Schumacher and colleagues and the reader is referred to these for further reading
[15;16;40].
9. Progesterone Regulation of Meiosis and Mitosis
During development of both vertebrates and invertebrates, P4 promotes meiosis to generate
germ cells [201;202;203]. P4 induced re-entry into the cell cycle at mediated by a membrane-
bound PR [201;204;205;206;207].
P4 promotion of meiosis is mediated by a rise in intracellular Ca2+[208;209;210]. In
Xenopus oocytes, P4 induces the resumption of meiosis (maturation) through a nongenomic
mechanism involving inhibition of adenylyl cyclase and reduction of intracellular cAMP.
However, P4 action in Xenopus oocytes is not blocked by pertussis toxin, indicating that
inhibition of the oocyte adenylyl cyclase is not mediated by the α subunit of classical Gi-type
G proteins [211]. Subsequent analyses indicate that P4 is likely inducing maturation by
antagonizing constitutive Gβγ-mediated inhibition of cell cycle progression[211].
Intracellular Ca2+ influx and inhibition of Gβγ are not the sole requirements for P4 regulation
of meiosis. Multiple laboratories have demonstrated that P4 activates MAPK signaling pathway
in oocytes and that this pathway is required for promotion of meiosis by P4 [212;213;214].
P4 activation of MAPK leads to the formation of the M-phase promoting protein complex
(CDC2 and cyclin B), which promotes G2 to M phase transition [215;216].
Mitotically, P4 has a complex function in the uterus and can be both inhibitory and stimulatory
for proliferation depending upon cell type (endometrial or stromal) the regimen of treatment,
the type of PR that is activated (PRA versus PRB), the dose of E2 and P4, and when in the
cycle P4 is administered [217;218;219;220;221;222]. In the endometrium, P4 inhibits
proliferation of endometrial cells whereas P4 is a proliferative agent in the stromal cells of the
uterus. Further, P4 inhibited proliferation in E2 primed uterus but not when administered alone
or with low dose E2. A progestinal agent in hormone therapy is added to antagonize endometrial
cell proliferation in the uterus [223]. In addition to P4 action in the uterus, P4 can promote
proliferation in the breast [224;225;226;227].
In the Women's Health Initiative, in which medroxyprogesterone acetate (MPA) was used as
the progestinal agent, an increased risk of breast cancer in the hormone therapy (HT) trial was
observed which did not occur in the estrogen only therapy (ET) [227;228;229;230;231;232].
The WHI HT trial also revealed an increased risk of invasive ovarian cancer and a reduced risk
of endometrial cancer [233;234]. The use of the progestin, MPA, in the WHI HT trials has
been proposed to be a major factor contributing to the increased cancer risk seen in this trial.
However, the tumorgenic properties of different progestogens have not been systematically
studied, and not all progestogen molecules have the same antagonistic or agonistic profiles
[235;236;237]. The impact of different progestogens on the proliferation of neural stem cells
or neural progenitors is currently unknown.
Brinton et al. Page 13
Front Neuroendocrinol. Author manuscript; available in PMC 2009 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
10. Progesterone and Estrogen Regulation of Neurogenesis and Neural
Progenitor Proliferation
As in the uterus [217;238], P4 regulation of mitosis of neural progenitors in brain has a complex
profile. Tanapat et al. have shown that ovariectomized rats treated with a high level of E2 have
enhanced hippocampal cell proliferation, whereas subsequent exposure to P4 resulted in
blockade of the E2-induced enhancement of cell proliferation [239]. In contrast to P4 regulation
of E2-induced neurogenesis in vivo, we have demonstrated that P4 alone enhances cell
proliferation in vitro (Wang et al., 2005). More recent results indicate that P4 induced a dose
dependent significant increase in rat neural progenitor cells (rNPC) proliferation as measured
by BrdU incorporation over a 24 hr exposure period with an EC100 value of 100 pM. Unlike
its metabolite steroid APα, the dose response curve for P4 was shallow but linear up to 1μM
whereas the dose response for APα was steeply linear followed by an inverse function at
1μM. Further, when compared to the dose response for E2-induced rNPC proliferation (EC100
of 250 nM), P4 induced a more consistent enhancement of rNPC proliferation. The time course
of P4-induced rNPC proliferation generated 2 important outcomes. First, P4-induced DNA
synthesis occurred rapidly within the first 1-4 hours of P4 exposure. Second, it appears that
P4-induced DNA synthesis does not persist beyond 6 hours and that by 8 hrs, P4 no longer
induces DNA synthesis. These data suggest that P4 is not driving rNPCs into prolonged or
uncontrolled proliferation. Lastly, we conducted a steroid specificity analysis which indicates
that P4 and its metabolite APα are both proliferative agents [240].
Our own work has demonstrated that the neurosteroid P4 metabolite, APα is a potent,
stereoisomer-specific promoter of neurogenesis of both rat hippocampal neural progenitor cells
and human cortical neural stem cells [241]. Allopregnanolone–induced proliferation was
isomer and steroid specific, in that the stereoisomer 3β-hydroxy-5β-pregnan-20-one and related
steroids did not increase 3H-thymidine uptake. Immunofluorescent analyses for the neural
progenitor markers, nestin and Tuj1, indicated that newly formed cells were of neuronal
lineage. Furthermore, microarray analysis of cell cycle genes and real time RT-PCR and
western blot validation revealed that allopregnanolone increased the expression of genes,
which promote mitosis and inhibited the expression of genes that repress cell proliferation.
Allopregnanolone-induced proliferation was antagonized by the voltage gated L-type calcium
channel blocker nifedipine consistent with the finding that allopregnanolone induces a rapid
increase in intracellular calcium in hippocampal neurons via a GABA type A receptor activated
voltage gated L-type calcium channel [242]. These data demonstrate that APα significantly
increased rNPC and hNSM proliferation with concomitant regulation in mitotic cell cycle genes
via a voltage gated L-type calcium channel mechanism.
APα-induced neurogenesis is a dose-dependent process, with concentrations in the low to mid
nanomolar range promoting proliferation and concentrations exceeding 1 μM significantly
inhibiting neurogenesis. The biphasic dose-response profile of APα-induced neurogenesis
could account for the disparity between our in vitro data and reports that APα decreases
neurogenesis in the rat dentate gyrus in vivo. In these in vivo studies, APα inhibited
neurogenesis of rat SVG cells following intracerebral ventricular injection of 7.8 mmoles of
APα [3;186]. Considering that the injected concentration is diluted into the cerebrospinal fluid
and the volume of the cerebrospinal fluid in a 300 g rat is ∼ 580 μl [243], the final concentration
of APα would be more than 50 μM. Thus, inhibition of neurogenesis at micromolar
concentrations of APα in this study is consistent with our dose response data, which
demonstrates inhibition of neural progenitor cells proliferation at micromolar concentrations
and promotion of neurogenesis at nanomolar concentrations [241]. Griffin and Mellon found
that early administration of APα substantially delays progression and severity of symptoms in
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a transgenic mouse model of Niemann-Pick Type C, a disease characterized by disrupted
neurosteroidogenesis [244].
While production of new neurons from proliferating stem/progenitor cells in the SGZ of the
dentate gyrus is maintained throughout life in multiple species including humans [245;246],
the magnitude of neurogenesis declines with age. Age-associated decline in neurogenic
potential in the dentate gyrus has been observed as early as middle age [247;248] and has been
proposed to contribute to age-related learning and memory impairments [249;250;251;252].
The mechanism underlying age-associated decline in neurogenesis remains to be fully
determined. However, loss of the growth factors FGF-2, IGF-1 and VEGF in the
microenvironment of the SGZ is a prime contributor to the reduced neurogenic potential of the
SGZ [253]. Recent studies have demonstrated that the levels of these three multiple stem/
progenitor cell proliferation factors decline early on during the course of aging in the
hippocampus [254;255]. Hippocampal levels of FGF-2, IGF-1, and VEGF are more than 50 –
60% decline lower in adult rats than in young rats [255]. These findings suggest that the
dramatic decline in dentate neurogenesis could be linked to reduced concentrations of FGF-2,
IGF-1, and VEGF in the hippocampus, as each of these factors can individually influence the
proliferation of stem/progenitor cells in the SGZ of the dentate gyrus. For example, FGF-2
enhances dentate neurogenesis in both neonatal and adult brain [255;256;257;258;259;260;
261;262], and intracerebroventricular (ICV) infusions of FGF-2 upregulate dentate
neurogenesis in the aged brain [247;262;263;264;265]. Likewise, ICV administration of IGF-1
increased dentate neurogenesis in the adult and aged brain [252;266;267]. VEGF can promote
dentate neurogenesis in both the intact and the injured adult brain following ICV administration
[268;269;270]. During neurogenesis, VEGF may act as a chemoattractant that specifically
targets FGF2-stimulated neural progenitors [271].
Growth factors regulate a myriad of cellular processes aside from neurogenesis. For example,
EGF has well-characterized proliferative effects on the endometrium. EGF gene expression
dramatically increases in the endometrial glands of pregnant mares at approximately 40 days
after ovulation [272]. This upregulation is maintained until at least day 250 of gestation and is
associated with an increase in EGF receptor binding sites in the endometrium [273]. The
expression of both IGF and TGFb1 is also upregulated during this time [274]. Administration
of varying doses and combinations of P4 and estrogen for 35 days yields negative or only
weakly positive EGF expression, whereas administration of only P4 for 40 days strongly
upregulated EGF expression irrespective of additional treatment with estrogen [275]. These
findings underscore the importance of P4 in regulation of growth factors and reveal a
mechanism for P4-associated cell proliferation in vivo.
Similar to EGF, IGF and TGF, expression of brain derived neurotrophic factor (BDNF) is
positively correlated with E2 and P4 levels and negatively correlated with menopausal age
[276]. Hormone replacement therapy restored plasma BDNF levels to levels seen in fertile
women during the follicular phase [276]. Circulating plasma levels of BDNF change during
the menstrual cycle, suggesting that P4 may regulate neurotrophin expression [276].
Modifications in BDNF circulating levels during the menstrual cycle suggest a potential role
for gonadal sex hormones in regulating neurotrophin expression, which has implications for
sustaining the regenerative milieu of the brain during the menopausal years.
Regulation of cell cycle entry by progesterone and its neurosteroid metabolites as therapeutic
regenerative agents will require careful analysis prior to development for restoration of neurons
lost due to neurodegenerative disease. In Alzheimer's disease (AD), cell cycle-specific gene
expression is upregulated [277] and, evidence indicates that mitotic signaling is dysregulated
[278]. In the aged and AD brain, both the pool of neural stem cells and their proliferative
potential are markedly diminished [247;279]. In addition, the level of potential regenerative
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factors is reduced in the brains of AD patients compared to age-matched controls [280]. Herrup
and colleagues have found that ectopic expression of cell cycle proteins predicts the site of
neuronal cell death in the AD brain[281], leading these investigators to propose that
dysregulation of various elements of the cell cycle contributes to regionally specific neuronal
death in AD. They also found that DNA replication precedes neuronal death in AD brain
[282]. More disturbing, cell cycle events precede neuronal death at all stages of AD, from mild
cognitive impairment to advanced AD [278]. This finding has important implications for
strategies targeting neurogenesis in the AD brain. Specifically, it suggests that promoting entry
into the cell cycle could potentially be a double-edged sword, with benefit to healthy brains
but with exacerbation of ectopic mitosis in brains destined to develop AD or with existing AD.
11. Progesterone and Regulation Alzheimer's Disease Pathology
A key hypothesis linking P4 to AD posits that P4 acts as an endogenous regulator of β-amyloid
(Aβ) metabolism. According to the widely but not universally embraced ‘amyloid cascade
hypothesis,’ AD pathogenesis is triggered by any of a number of events that have the final
common endpoint of increasing the pool of soluble Aβ [283;284;285]. In turn, elevated soluble
Aβ leads to the formation of an array of soluble oligomeric, minimally soluble aggregated, and
eventually insoluble fibrillar Aβ species, all of which are linked in a variety of ways to
neurodegenerative cascades [286;287;288;289;290;291;292;293]. Thus, factors that have the
net effect of reducing the pool of soluble Aβ are thought to represent potentially powerful
strategies for preventing the development of AD [294;295].
Neurosteroids have recently been measured in various brain regions of aged Alzheimer's
disease patients and aged non-demented controls by GC/MS [296]. In Alzheimer's patients,
there was a general trend toward lower levels of neurosteroids in different brain regions, and
neurosteroid levels were negatively correlated with two biochemical markers of Alzheimer's
disease, the phosphorylated tau protein and the beta-amyloid peptides [296]. The formation of
these metabolites within distinct brain regions negatively correlated with the density of beta-
amyloid deposits.
Available evidence suggests that E2, like P4, may influence Aβ levels. In women, E2 status has
been linked to the development of AD [237]. Schonknecht and colleagues found that levels of
E2 in cerebral spinal fluid are lower in AD patients than in non-AD controls and that, in the
AD group, E2 levels are inversely correlated with Aβ1-42 levels [297]. In accord with this
finding, several cell culture studies have shown that E2 decreases Aβ production, presumably
increasing the non-amyloidogenic cleavage of amyloid precursor protein (APP) via α-secretase
[298;299;300;301;302;303]. The physiological significance of this effect has been confirmed
by in vivo studies investigating the relationship between circulating E2 concentrations and brain
levels of Aβ. Depletion of endogenous E2 via ovariectomy results in a significantly increases
levels of soluble Aβ in brains of mice [304] and guinea pigs [305]. Importantly, this effect is
partially reversed by E2 replacement. Furthermore, E2 reduces pools of soluble [306;307] and
deposited Aβ [307] in mouse models of AD, strongly implicating E2 as a regulator of AD
pathogenesis. Unexpectedly, two recent studies using transgenic mouse models of AD have
found weak [308] or absent evidence [309] that E2 reduces insoluble pools of Aβ. Several
factors may have contributed to these negative results, including the transgenic strains, the
relevant pool of Aβ, and the difference between estrogen levels in circulation and in the brain
[310]. Prior investigations of Aβ regulation by ovarian sex steroids have used ovariectomy
models (which depletes endogenous E2 and P4) combined with E2, but not P4, replacement
[305;306;307;308;309].
While E2 replacement is beneficial in regulation of Aβ metabolism, the interaction between
E2 with P4 is more clinically relevant. That is, how are Aβ levels affected when P4 acts in
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concert with E2? Our group has recently addressed this question in the 3xTg-AD mouse model
of AD. Our results suggest that continuous E2, but not P4 treatment attenuates the acceleration
of Aβ accumulation and memory deficits observed in ovariectomized mice. More importantly,
in animals receiving both hormones, P4 blocked the beneficial effect of E2 on Aβ accumulation
[2].
12. Progestogens, Progestins and Metabolism
Many progestogens are used therapeutically among these, P4 is the only naturally occurring
progestogen (see Table 1). The remainder, which are synthetic, are referred to as progestins
(see Table 1)[236]. Progestins are classified on the basis of their chemical structure, since the
structures of these molecules vary widely. Progestins can be divided into those related in
chemical structure to P4 and those related chemically to testosterone. The classification scheme
and the names of progestins in each of the categories are summarized in Table 1. This
classification scheme does not denote the chemical source of the compounds.
Progestins related to P4 are characterized by the presence or absence of a methyl group on
carbon 10, and are subdivided into pregnanes (21 carbons) and 19-norpregnanes (20 carbons)
(see Tables 1 and 2) [41]. The pregnanes and 19-norpregnanes can be further separated into
compounds with and without an acetyl group. One of the best known and most widely used of
these progestins is MPA, which is classified as an acetylated pregnane. All of the 19-
norpregnane progestins have been used primarily in Europe and not in the United States.
Unlike the progestins related to P4, which are first subdivided on the basis of the number of
carbons (21 versus 20), those related to testosterone are first subdivided on the basis of whether
or not they contain an ethinyl group. The ethinylated progestins are subdivided further into
those related to the parent steroid, estrane, and those related to 13-ethylgonane. Both estranes
and 13-ethylgonanes lack a methyl group at carbon 10. The estrane group of progestins consists
of norethindrone and its prodrugs, namely norethindrone acetate, ethynodiol diacetate,
norethynodrel, and lynestrenol. These prodrugs, which are considered part of the norethindrone
family, have been widely used for hormone therapy and/or contraception. Although tibolone
is also a prodrug and is listed in the estrane category, it is not converted to norethindrone.
Instead, it is transformed to other active metabolites.
The 13-ethylgonanes contain an ethyl group on carbon 13 of the basic steroid nucleus (gonane).
This category of progestins, sometimes referred to as the levonorgestrel family, consists of
levonorgestrel and the levonorgestrel derivatives desogestrel, norgestimate, and gestodene.
The latter three progestins are often referred to as the new progestins, as they have been
marketed relatively recently. In contrast, levonorgestrel has been used for many years.
Norgestimate and desogestrel, but not gestodene, are prodrugs. However, only norgestimate
is converted to levonorgestrel. Norgestimate is also converted to deacetylated norgestimate
(levonorgestrel-3-oxime), which has progestational activity. Desogestrel is converted to its
active form, 3-ketodesogestrel. Gestodene has inherent progestational activity, but is not
approved for use in the United States.
13. Progestogen metabolism
With the exception of P4, little is known about the metabolism of most progestogens. Baulieu
first discovered that P4 is converted to neuroactive metabolites in the brain [1;15;27]. This has
now been well established by many laboratories and documented in multiple species including
the rodent and human. Neurosteroids such as APα are synthesized in the central and peripheral
nervous system, primarily by myelinating glial cells, but also by astrocytes and several neuron
types [15;311;312;313]. A region-specific expression pattern of P4-converting enzymes in
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brain is evident in both the hippocampus and cortex of rodent and human brain [311;312;
313;314]. The P4-converting enzymes 5α-reductase and 3α-hydroxysteroid dehydrogenase are
expressed in the hippocampus of both the rodent and human brain and convert P4 to its 5α,
3α-reduced metabolites (e.g., APα). Remarkably, these enzymes are also present and functional
in pluripotential progenitors [315]. The conversion of P4 to its 5α, 3α-reduced metabolites can
be blocked by 5α-reductase inhibitors, such as finasteride.
Of the progestins, the metabolism of norethindrone and levonorgestrel is the best characterized
(see Table 2). These compounds undergo extensive reduction at the double bond between
carbons 5 and 6 and the carbonyl group at carbon 3, resulting in the formation of dihydro- and
tetrahydroderivatives. They can also undergo hydroxylation. Surprisingly little is known about
the metabolism of the most widely used progestin, MPA. This compound, like other progestins
structurally related to P4 or testosterone, contains a double bond between carbons 5 and 6 as
well as a ketone group at carbon 3. Therefore, it is likely to undergo extensive reduction at
these functional groups. Unlike the neuroactive metabolites of P4 (e.g., APα), exceedingly little
is known about the neuroactive properties of progestin metabolites.
14. Progesterone and PRs: Translational and therapeutic challenges
Relative to estrogen neurobiology, the non-reproductive neural functions of P4 and the basic
genomic, signaling and cell biology of these processes are just emerging. Progesterone and its
neuroactive metabolites can promote the viability of neurons and function of glial cells within
both the central and peripheral nervous system. While there is a substantial body of evidence
regarding the pleiotrophic actions of P4 [16], much remains to be determined regarding the
specific PR required and the associated effector mechanism(s) of action. The use of P4 as a
myelinating agent and as a treatment for traumatic brain injury highlight the basic science and
clinical importance of understanding the direct effects of P4 and other progestogens. It is
interesting to note that women have a greater risk of developing the demylinating disease
multiple sclerosis with a frequent onset at menopause [316]. Given the significant impact of
P4 and its metabolite, allopregnanolone (tetrahydroprogesterone) on remylination following
injury and preventing age-associated myelin loss, the potential therapeutic use of P4 for
remylination is substantial in both men and women. Of particular concern, given the results of
the WHI and WHIMS trials, is the impact of clinically used progestins on neurological function.
While progestogens in hormone therapy are given to reduce the risk of uterine cancer, these
agents potentially exert effects in brain. Collectively, we know little regarding the impact of
different progestins on neural function either acutely or chronically. The wide distribution of
progesterone receptors in brain suggests that this gonadally and brain derived steroid plays a
significant role in neural function, which awaits continued discovery.
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Fig. 1.
Gene structure and functional domains of rat cPRA and cPRB. In rat, the classical progesterone
receptor is composed of 8 exons with a 3100-bp coding region and 5′- and 3′-untranslated
region. Both cPRB and cPRA are transcribed from this gene, but use alternative initiation
codons (red horizontal arrows) driven by different promoters. The cPRs have a highly
conserved DNA binding domain (DBD), an activation function1 (AF1) domain immediately
upstream of the DBD, a hinge region downstream of the DBD, as well as a ligand binding
domain (LBD) and a C-terminal AF2 domain. An inhibition factor (IF) is present upstream of
AF1. The N-terminus of cPRB contains an AF3 domain, which acts in synergy with AF1 and
AF2.
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Fig. 2.
Splice variants of cPR. A) Variants can be generated through insertion of T or S between exon
3 and 4 as well as through insertion of a or b between exon 4 and 5. B) Alternatively, variants
can be generated through exon skipping. In PR-c, exon 1 is omitted. In PR-S and PR-T, exons
1-3 are omitted, but the 5′-untranslated exons S and T are retained.
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Fig. 3.
Distribution of the 25 Dx PR transmembrane domain in the rat brain. The classical progesterone
receptors PRA and PRB have been localized to regions throughout the brain using the indicated
methods.
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Fig. 4.
Model of progesterone-induced neuroprotective signaling. Progestogen prevents synaptic
dysfunction associated with aging and neurodegeneration through (1) ligand activation of a
progesterone receptor, (2) which initiates second messenger signaling cascades (3) to promote
neuronal survival. These signaling cascades converge on mitochondrial function to protect
against against toxic insults and include the passive prevention signaling pathway and the active
protection signaling pathway. In the passive prevention signaling pathway, both ERK/CREB/
Bcl-2 and Akt pathways are simultaneously activated, which (4) enhances mitochondrial
function and enables neurons to better withstand neurodegenerative insults. The active
protection pathway acts to block Aβ-induced JNK activation and mitochondrial dysfunction.
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Table 1
Classification of Progestogens
I. Natural II. Synthetic Progestins
A. Structurally Related to Progesterone Structurally Related to Androgen
Progesterone 1 Pregnane Derivatives
a. Acetylated: medroxyprogesterone acetate,
megestrol acetate, cyproterone acetate,
chlormadinone acetate, medrogestone
b. Non-acetylated: dydrogesterone
2 19-Norpregnane derivatives
a. Acetylated: nomegestrol acetate
b. Non-acetylated: demegestone,
trimesgestone, promgeestone, nesterone
1 Ethinylated
a. Estranes: norethindrone,
norethynodrel, lynestrenol,
norethindrone acetate,
ethynodiol diacetate, tibolone
b. Gonanes: levonorgestrel,
desogestrel, norgestimate,
gestodene
2 Non-ethinylated: dienogest, drospirenone
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Table 2
Structures of selected progestogens and list of their active metabolites
Category Progestogens Structure Active Compound of
Prodrug
Natural Progestogens Progesterone
Pregnane
(Acetylated)
Medroxyprogesterone Acetate
Megestrol Acetate
Chlormadionone Acetate
Cyproterone Acetate
Pregnane
(Non-acetylated)
Dydrogesterone
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Category Progestogens Structure Active Compound of
Prodrug
Medrogestone
19-Norpregnane
(Acetylated)
Nomegestrol Acetate
Nesterone
Norpregnane
(Non-acetylated)
Trimegestone
Demegestone
Promegestone
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Category Progestogens Structure Active Compound of
Prodrug
Tesosterone Derivative
(Estranes)
Norethindrone
Noethindrone acetate Norethindrone
Ethynodiol diacetate Norethindrone
Norethynodrel Norethindrone
Lynestrenol Norethindrone
Tibolone Δ4-Tibolone
3α-OH-Tibolone
3β-OH-Tibolone
Testosterone Derivatives
(Gonanes)
Levonorgestrel
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Category Progestogens Structure Active Compound of
Prodrug
Desogestrel 3-Ketodesogestrel
Norgestimate Levonorgestrel-3-oxime
Levonorgestrel
Gestodene
Testosterone Derivatives
(Non-ethinylated)
Drospirenone
Dienogest
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